Fulcrum Therapeutics, Inc. Stock News

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -25.76% and 28.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the st

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically

Fulcrum lost hugely this month after announcing data from an early Sickle Cell Disease trial. The other program is also beset with issues.

- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development

Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Naomi Aoki - SVP, Corporate Communications & IR Bryan Stuart - President & CEO Ju

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -1.59% and 24.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the st

Fulcrum Therapeutics, Inc. (FULC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street ana

Investors need to pay close attention to Fulcrum (FULC) stock based on the movements in the options market lately.

Fulcrum Therapeutics, Inc. (FULC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the

Event to discuss unmet need in FSHD, key measures of disease progression and Phase 3 REACH trial

Oppenheimer has started the coverage on the clinical-stage biopharmaceutical company Fulcrum Therapeutics (FULC) with an Outperform recommendation citing the potential of FTX-6058,…

The average of price targets set by Wall Street analysts indicates a potential upside of 178.8% in Fulcrum Therapeutics, Inc. (FULC). While the effectiveness of this highly sought-after metric is ques

Fulcrum Therapeutics Inc (NASDAQ: FULC ) plans to initiate REACH, a Phase 3 trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD), in Q2 of 2022 . FSHD is characterized by fat infiltration of skeletal muscle leading to muscular atrophy involving the face, scapula and shoulders, upper arms, and abdomen. REACH will be a randomized, double-blind, placebo-controlled, multi-national trial to evaluate the efficacy and safety of … Full story available on Benzinga.com

Fulcrum Therapeutics (FULC) plans to begin a phase 3 trial, called REACH, of losmapimod in people with facioscapulohumeral muscular dystrophy ((FSHD)) in Q2 2022.FSHD is a rare…